Aeruginosin 298-A was isolated from the freshwater cyanobacterium Microcystis aeruginosa (NIES-298) and is an equipotent thrombin and trypsin inhibitor. A variety of analogs were synthesized to gain insight into the structure-activity relations. We developed a versatile synthetic process for aeruginosin 298-A as well as several attractive analogs, in which all stereocenters were controlled by catalytic asymmetric phase-transfer reaction promoted by twocenter asymmetric catalysts and catalytic asymmetric epoxidation promoted by a lanthanide-BINOL complex. Furthermore, serine protease inhibitory activities of aeruginosin 298-A and its analogs were examined. P roteolytic reactions control many important biologic processes; thus, the discovery of new selective proteolysis inhibitors continues to receive significant attention (1). Several serine proteases have been selected as potential therapeutic targets, such as the coagulation enzyme factors Xa, VIIa, and IIa (thrombin) (2) and urokinase-type plasminogen activator (3-5). The catalytic sites of the different serine proteases involved have a highly homologous region (2); therefore, engineering high selectivity would be especially challenging. Cyanobacteria produce several unique biologically active peptides, such as microcystins, microviridin, nodularin, and puwainaphycins. Aeruginosin 298-A (1a) was isolated by Murakami and coworkers from the freshwater cyanobacterium Microcystis aeruginosa (NIES-298) (6) and is an equipotent thrombin and trypsin inhibitor (7) (Fig.  1 ). Since 1994, Ͼ10 aeruginosins have been isolated by Murakami (6-9), along with microcin SF608, which was isolated by Carmelli and coworker (10). These compounds have a tetrapeptide-like structure including nonstandard ␣-amino acids such as 3-(4-hydroxyphenyl)lactic acid (Hpla) and 2-carboxy-6-hydroxyoctahydroindole (Choi). Of the aeruginosin family, aeruginosin 102-A (1b) is reported to have the highest activity (7, 8) . More potent analogs in terms of selectivity and activity, however, need to be developed. Although the total synthesis of 1a was reported by Bonjoch et al. (11, 12) and Wipf and Methot (13), the development of a highly versatile synthetic method is required to gain insight into the structure-activity relations by the syntheses of a variety of analogs. To address this issue, we applied asymmetric phase-transfer catalysis (PTC) promoted by two-center catalysts, which were recently developed by our group (14), to the syntheses of 1a as well as its analogs. Here, we report the enantioselective syntheses of aeruginosin 298-A and its analogs (15) by using asymmetric PTC and the catalytic asymmetric epoxidation of an ␣,␤-unsaturated imidazolide, which was also recently developed by our group (16) (17) (18) (19) (20) (21) (22) . Moreover, serine protease inhibitory activities of 1a and its analogs were examined, leading to the future discovery of analogs possessing higher and more selective protease inhibitor potencies than those of the natural products. The knowledge gained provides important information regarding the structure-activity relation within the aeruginosins' molecular framework and sets the stage for further advances in the field.
P
roteolytic reactions control many important biologic processes; thus, the discovery of new selective proteolysis inhibitors continues to receive significant attention (1) . Several serine proteases have been selected as potential therapeutic targets, such as the coagulation enzyme factors Xa, VIIa, and IIa (thrombin) (2) and urokinase-type plasminogen activator (3) (4) (5) . The catalytic sites of the different serine proteases involved have a highly homologous region (2); therefore, engineering high selectivity would be especially challenging. Cyanobacteria produce several unique biologically active peptides, such as microcystins, microviridin, nodularin, and puwainaphycins. Aeruginosin 298-A (1a) was isolated by Murakami and coworkers from the freshwater cyanobacterium Microcystis aeruginosa (NIES-298) (6) and is an equipotent thrombin and trypsin inhibitor (7) (Fig.  1 ). Since 1994, Ͼ10 aeruginosins have been isolated by Murakami (6) (7) (8) (9) , along with microcin SF608, which was isolated by Carmelli and coworker (10) . These compounds have a tetrapeptide-like structure including nonstandard ␣-amino acids such as 3-(4-hydroxyphenyl)lactic acid (Hpla) and 2-carboxy-6-hydroxyoctahydroindole (Choi). Of the aeruginosin family, aeruginosin 102-A (1b) is reported to have the highest activity (7, 8) . More potent analogs in terms of selectivity and activity, however, need to be developed. Although the total synthesis of 1a was reported by Bonjoch et al. (11, 12) and Wipf and Methot (13) , the development of a highly versatile synthetic method is required to gain insight into the structure-activity relations by the syntheses of a variety of analogs. To address this issue, we applied asymmetric phase-transfer catalysis (PTC) promoted by two-center catalysts, which were recently developed by our group (14) , to the syntheses of 1a as well as its analogs. Here, we report the enantioselective syntheses of aeruginosin 298-A and its analogs (15) by using asymmetric PTC and the catalytic asymmetric epoxidation of an ␣,␤-unsaturated imidazolide, which was also recently developed by our group (16) (17) (18) (19) (20) (21) (22) . Moreover, serine protease inhibitory activities of 1a and its analogs were examined, leading to the future discovery of analogs possessing higher and more selective protease inhibitor potencies than those of the natural products. The knowledge gained provides important information regarding the structure-activity relation within the aeruginosins' molecular framework and sets the stage for further advances in the field.
Materials and Methods
Chemical Synthesis. Details for the syntheses of aeruginosin 298-A and its analogs are provided in Supporting Materials and Methods, which is published as supporting information on the PNAS web site (see also ref. 15 ).
General Procedure for the Catalytic Asymmetric Phase-Transfer Alkylation. A solution of 4-(triisopropylsilanyloxy)benzyl bromide (Ϸ0.2 M in toluene, 7.0 ml, 3.5 mmol, 5.0 eq) was added to a mixture of N-(diphenylmethylene)glycine tert-butyl ester (4) (207 mg, 0.70 mmol) and phase-transfer catalyst (S,S)-2a (67 mg, 0.070 mmol, 10 mol %) in CH 2 Cl 2 (3.0 ml, total 0.07 M) at Ϫ70°C. CsOH⅐H 2 O (1.18 g, 7.0 mmol, 10 eq) was added directly to the reaction mixture at the same temperature. After stirring for 72 h at the same temperature, the reaction was quenched by the addition of water followed by diethyl ether. After vigorous stirring at room temperature, both organic and aqueous layers were transferred to a separation funnel by simple decantation. The organic layer was separated and washed with brine. The combined aqueous layers were reextracted with diethyl ether and the combined organic layers were dried over Na 2 SO 4 . After concentration in vacuo, the residue was purified by flash column chromatography (silica gel deactivated with Et 3 N, hexane only to 5% EtOAc in hexane) to give D-3b (343.2 mg, 88%) and excess electrophile was recovered (820 mg, 85%).
The phase-transfer catalyst was also recovered (60 mg, 90%) by the following procedure. After quenching the reaction, the phase-transfer catalyst was deposited as a white solid between the organic and aqueous layers. After stirring vigorously, the white solid was stuck to the glass wall. The organic layer, which contained the product, and aqueous layer were transferred into a separation funnel by simple decantation. The residual solid was dissolved with 30% MeOH in CH 2 Cl 2 and filtered through filter paper to remove inorganic salts. The catalyst was obtained as a white powder after evaporation of the solvent [Ϸ90% yield for 2a (X ϭ I) and Ϸ80% yield for 2c (X ϭ BF 4 )], which was used for the next phase-transfer alkylation without further purification.
The product D-3b was treated with 0.5 N aqueous citric acid solution (1.5 ml) in tetrahydrofuran (THF) (6.2 ml) for 90 min at room temperature. The mixture was quenched with water and the aqueous phase was basified with solid NaHCO 3 , extracted with CH 2 Cl 2 (three times), and dried over Na 2 SO 4 . After concentration in vacuo, the residue was purified by flash column chromatography (silica gel, 40-60% EtOAc in hexane) to give D-7b General Procedure for the Catalytic Asymmetric Epoxidation. A solution of La(O-i-Pr) 3 (0.2 M in THF, 5.0 ml, 1.0 mmol, 10 mol %) was added to a mixture of (S)-BINOL (286 mg, 1.0 mmol, 10 mol %), triphenylphosphine oxide (835 mg, 3.0 mmol, 30 mol %), and MS 4A (10 g) in dry THF (100 ml, 0.1 M) at room temperature. After stirring for 45 min at the same temperature, a solution of TBHP (5.0 M in decane, 4.8 ml, 24 mmol, 2.4 eq) was added at 4°C. After stirring for 10 min at 4°C, imidazolide 6 (4.47 g, 10 mmol, 1.0 eq) was added directly and the mixture was stirred at room temperature for 90 min. The reaction was quenched by the addition of 1% aqueous citric acid solution at 4°C. The mixture was extracted with ethyl acetate (two times), and the combined organic layers were washed with 2% aqueous sodium thiosulfate followed by brine and dried over Na 2 SO 4 .
After concentration in vacuo, the residue was purified by flash column chromatography (silica gel, 5% EtOAc in hexane) to give epoxy peroxyester 5 (3.88 g, 95%) as a pale yellow oil.
Biologic Assay. Trypsin and the substrate (N ␣ -benzoyl-D,Larginine-p-nitroanilide) were purchased from Sigma-Aldrich. Trypsin was dissolved in 50 mM Tris⅐HCl (pH 7.6) to prepare 300 units/ml solution. The substrate (43.3 mg), dissolved in DMSO (1 ml), was diluted with 50 mM Tris⅐HCl (pH 7.6, 100 ml). The assay mixture containing 50 mM Tris⅐HCl buffer (pH 7.6, 30 l), enzyme solution (50 l), and test solution (20 l) were added to each microtiter plate well and preincubated at 37°C for 5 min. Substrate solution (100 l) was then added to begin the reaction. The absorbance of the well was read immediately at 405 nm. The developed color was measured after 30 min incubation at 37°C. [28] [29] [30] [31] [32] , only a few synthetic applications for complex natural products have been reported (23) . Recently, we developed two-center catalysts that promote phase-transfer alkylations and Michael reactions with high substrate generality (14) . The catalysts 2 (Scheme 1) are advantageous in terms of catalyst accessibility (five-step process from commercial L-or D-tartrate on large-scale by using only inexpensive reagents and simple operations) and versatility (tunable substituents: R 4 , R 5 , and Ar). Thus, we planned to use this PTC to synthesize the three of four ␣-amino acid portions (Leu, Choi, and Argol portions) of 1a and its analogs. For the synthesis of the Hpla portion and the following coupling reaction with the Leu portion, we chose a strategy based on the catalytic asymmetric epoxidation of an ␣,␤-unsaturated imidazolide (18, 19, 22) and the subsequent one-pot process including a peptide coupling reaction of the corresponding ␣,␤-epoxy peroxyester and ␤-selective epoxide opening reaction (20, 22) .
Results and Discussion
Synthesis of the D-Leu Portion. When using 10 mol % of (S,S)-2a, phase-transfer alkylation of 4 proceeded smoothly to afford a variety of ␣-amino acids (14, 15) . For the synthesis of 1a (D-Leu portion), methallyl bromide was used as an electrophile to afford D-3a [93%, 91% enantiomeric excess (ee)]. Based on the structure of aeruginosin 102-A (1b), we also synthesized the D-Tyr analog D-3b (88%, 92% ee) and the D-Phe(4-F) analog D-3c (93%, 94% ee). During the scaling-up of the reaction, we found that after quenching the reaction with water and ether, catalyst 2 was deposited as a white solid and easily recoverable in Ϸ90% yield just by simple decantation (15) . This finding suggests that catalyst 2 is extremely stable even under strongly basic conditions in contrast to commonly used Cinchona alkaloid derived catalysts (24) (25) (26) (27) . The recovered catalyst had the same catalyst efficiency (15) . Hydrolysis of benzophenone imine of 3 by acid treatment (0.5 M aqueous citric acid) or hydrogenolysis conditions (H 2 , catalyzed by Pd-C, MeOH) afforded the corresponding amino esters 7 in high yield and they were used for the next coupling reaction (vide infra). In the case of fluoride analog D-7c, its optical purity was further enriched by recrystallization (Ͼ99% ee, 52%) (Scheme 2).
Synthesis of the L-Choi Portion. The L-Choi portion was previously synthesized from L-Tyr derivatives (11) (12) (13) . Although L-7b can be converted to L-Choi via L-Tyr, we chose a more direct method including a one-pot multistep reaction. Synthesis of Bonjoch's intermediate 11a (11, 12) was accomplished from 9 through the 1,4-addition of an amine moiety. To synthesize the 1,4-addition precursor 9 in a catalytic asymmetric manner, we used 8, which was prepared from anisyl alcohol (15) , as an electrophile for the asymmetric PTC. When using (R,R)-2a as a catalyst, the asymmetric PTC of 4 and 8 proceeded smoothly to afford the desired product L-3d in 80% yield and 88% ee. Treatment of the product L-3d with 4 N HCl in methanol promoted deprotection of the benzophenone imine and ketal, transesterification, migration of the CAC double bond, and then 1,4-addition of the resulting amine to enone, leading to the bicyclic compound 10 in 72% yield (one-pot, five reactions). After benzylation, the key intermediate was obtained in 84% yield as a mixture of diastereomers (11a:11b ϭ 1:2). The undesired isomer 11b was transformed to the desired 11a under acidic conditions through presumably retro 1,4-addition and dienolate formation leading to a more stable 11a (78%; 11a:11b ϭ 8:1), which was successfully converted to the key intermediate 13 (71% in two steps) by following Bonjoch's procedure (11, 12) . In addition, optically pure 13 was obtained by recrystallization (Ͼ99% ee, 77%) (Scheme 3).
Synthesis of the L-Argol Portion. The L-Argol portion 15a was synthesized by catalytic asymmetric phase-transfer alkylation or Michael addition. In the former process, the synthesis of 15a began with the phase-transfer alkylation of 4 by using allyl bromide and (R,R)-2a, affording L-3e in 79% yield and 91% ee. Then, allyl compound L-3e was successfully converted to 15a through introduction of the guanidine moiety by the Mitsunobu reaction (33) . In the later process, 15a was synthesized by the phase-transfer Michael reaction of 4 to benzyl acrylate by using (S,S)-2b catalyst, which was prepared from less expensive Ltartrate, because our two-center catalyst 2 has opposite enantiofacial selectivity in alkylations and Michael reactions (14) . The reported conditions for the Michael reaction, however, were not very effective and gave 16 in 74% ee with moderate reactivity (Ϫ30°C, 18 h, 85% yield), even when using 10 eq of Cs 2 CO 3 . To overcome these problems, we reexamined the Michael reaction. In contrast to the alkylation, in principle, only a catalytic amount of base is necessary to promote the Michael reaction, although most of the reported conditions for the Michael reaction used an excess amount of base. Indeed, in the presence of 0.5 eq of Cs 2 CO 3 , the catalytic asymmetric phase-transfer Michael reaction was completed in an analogous reaction time with little decrease in enantioselectivity. At this point, we expected that in the presence of only catalytic amounts of base, the counter anion of the catalyst would affect reactivity. Examination of counter anion effects indicated that hard counter anions effectively enhanced the reactivity of the Michael reaction and in some cases enantioselectivity was also improved (15) . Among the examined counter anions, tetrafluoroborate gave the best result. When tetrafluoroborate catalyst (S,S)-2d was used, the reaction completed in 10 h at the same temperature (Ϫ30°C) with only 0.5 eq of Cs 2 CO 3 , and the enantioselectivity was improved to 81% (86% ee at Ϫ60°C). Furthermore, optically pure 16 was obtained by recrystallization (Ͼ99% ee, 43%). To the best of our knowledge, this is the first example of such a drastic counter anion effect in PTC. The counter anion effect was also observed in alkylation, even with an excess amount of hydroxide (10 eq of CsOH) (15) . This might be a characteristic property of our two-center catalyst. Even when the catalyst makes a complex with the enolate, one of two original counter anions of the catalyst might remain just beside the catalyst. The results of the recovery of the catalyst described above also support our assumption. The tetrafluoroborate catalyst (R,R)-2c successfully improves the results of phase-transfer allylation of 4 to L-3e (85%, 93% ee). This condition was also applied to the synthesis of the quaternary ␣-amino ester 18 (76%, 88% ee), which was further transformed to 15b by using the same procedure (Scheme 4).
Synthesis of the D-Hpla Portion and Coupling Reaction with the D-Leu
Portion. The D-Hpla portion was prepared based on catalytic asymmetric epoxidation (refs. 18, 19, and 20 ; for the effects of Ph 3 PAO, see refs. 34 and 35). We recently reported the catalytic asymmetric epoxidation of ␣,␤-unsaturated imidazolides by the LaOBINOLOPh 3 AsAO (1:1:1) complex 19 or LaOBINOLOPh 3 PAO (1:1:3) complex 20 and efficient transformations of the corresponding epoxidation products (18) (19) (20) 22) . This is the first example of a general catalytic asymmetric epoxidation of ␣,␤-unsaturated carboxylic acid derivatives. The epoxidation of ␣,␤-unsaturated imidazolide 6 gave the corresponding ␣,␤-epoxy peroxyester 5 in 95% yield and 94% ee as a stable compound, which was isolated by using common flush column chromatography and can be stored for at least 2 months in a refrigerator (4°C). On the other hand, ␣,␤-epoxy peroxyesters are so-called active-esters; thus, many kinds of nucleophiles can react very smoothly at the carbonyl carbon in preference to the epoxide, affording a variety of ␣,␤-epoxy carbonyl compounds such as ␣,␤-epoxy esters, ␣,␤-epoxy amides, ␣,␤-epoxy aldehydes, and ␥,␦-epoxy ␤-keto esters (18, 19, 22) . In fact, a coupling reaction of the D-Hpla portion and the D-Leu portion was accomplished just by mixing 5 and 7a in THF without any reagent (15) . After completion of the coupling reaction, the crude dipeptide was directly treated with a catalytic amount of palladium on charcoal under hydrogen atmosphere to give the desired left dipeptide: D-Hpla-D-Leu portion 21a in very high yield as a mixture of diastereomers (97%, two steps, 11:1) (20, 22) . Diastereomers were separated by flash column chromatography at this stage. In the same way, D-Hpla-D-Tyr analog 21b and D-Hpla-D-Phe(4-F) analog 21c were also synthesized (Scheme 5).
Synthesis of L-Choi-L-Arg Portion. Subsequent saponification of the L-Choi portion 13 and a coupling reaction with the L-Arg portion L-15a by using EDC-HOBt gave the desired right dipeptide: L-Choi-L-Arg portion 22a in 88% yield as a mixture of diastereomers. Although a protection of the secondary alcohol in the Choi portion is not necessary for the synthesis of 1a, to synthesize a variety of analogs such as the Argal (R 2 ϭ CHO) derivative from the same tetrapeptide intermediate, triisopropylsilyl (TIPS) protection of the secondary alcohol was performed to give 23a as a mixture of diastereomers (72% in three steps, 12:1), which was separated at this stage. The synthesis of the L-Choi-D-Arg analog 23c was performed in the same way. Even in the case of the quaternary ␣-amino acid analog, the coupling reaction proceeded smoothly, leading to the corresponding L-Choi-L-Arg(␣-Me) analog 23b after TIPS protection and separation of the diastereomer (Scheme 6).
Completion of the Asymmetric Syntheses of Aeruginosins. To synthesize various analogs from the same tetrapeptide intermediate, the secondary alcohols were protected with TIPS. After TIPS protection of the secondary alcohol in the L-Hpla portion of 21 with TIPSOTf and i-Pr 2 NEt, TMSOTf (36) was added to the reaction directly under reflux conditions, affording the left segment 24 after aqueous work-up. On the other hand, the right segment 25 was prepared by deprotection of the Boc group with ZnBr 2 (37, 38) . When HOBt containing a coupling reagent such as PyBOP [benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate] (39) was used for the coupling reaction of both dipeptide segments (1:1 ratio), tetrapeptide 26a (40%) was obtained with partial racemization at the Leu portion (Ϸ20%). Screening the coupling conditions indicated that the coupling reaction with HATU [O-(7-azabenzotriazol-1-yl)-N,N,NЈ,NЈ-tetramethyluronium hexaf luorophosphate] (40) proceed smoothly through the HOAt ester to afford superior results (54% from 24a and 24c) and produced a negligible amount of the diastereomer (Ͻ5%). For the transformation of the methyl ester to the corresponding primary alcohol, reduction using LiBH 4 in THF was superior. Addition of an excess amount of LiBH 4 in a one-portion or at a higher reaction temperature (room temperature), however, resulted in not only the desired reduction but also partial deprotection of the Cbz group at the Ј position (R 8 ).
Although Cbz groups will be removed under hydrogenolysis conditions in the final stage, based on the ease of handling especially after removal of the TIPS groups, the reduction was performed at 4°C with multiportion addition of LiBH 4 , affording the primary alcohol 27a (54%, 93% conversion) without over reaction. Finally, subsequent deprotection of TIPS and Cbz groups provided aeruginosin 298-A (1a). Surprisingly, there were several disagreements between the 1 H and 13 C NMR data and the reported data (6, (11) (12) (13) . According to previous procedures for the purification (6, 11, 12) C NMR data were then identical with the reported data. Moreover, six additional analogs 28b-f were synthesized in a similar way, except for 28d (15) . In this case, the reduction of methyl ester was performed at room temperature to afford Ј-Cbz deprotected primary alcohol 27d due to the low reactivity at 4°C. Furthermore, the L-Arg analog 28g (R 2 ϭ CO 2 H) was synthesized from 26b by deprotection of TIPS and Cbz groups and saponification of the methyl ester (Scheme 7).
Protease Inhibitory Activities of Aeruginosin Analogs. The synthesized aeruginosin 298-A (1a) and its analogs 28b-g were screened for inhibitory activities against the serine protease trypsin. IC 50 values are tabulated in Table 1 . Although this is a preliminary result, the data reveal several important structure-activity relations. Replacing D-Leu (entry 1) of 1a with D-Tyr (entry 2) or D-Phe(4-F) (entry 3) slightly decreased the inhibitory activities. In striking contrast to the Leu portion, the importance of the L-Argol portion was apparent by the results of L-Argol(␣-Me) analog 28d (entry 4) and D-Argol analogs 28e and f (entries 5 and 6). Introduction of a methyl group or epimerization at the ␣-position of the L-Argol portion resulted in almost complete loss of activity. These findings along with the result of the much less active cyclic hemiaminal derivative aeruginosin 103-A (9) suggest that the conformation of the Argol portion, especially the guanidine side-chain, is critical for the trypsin inhibitory activity. Moreover, based on the results of entries 1 and 2, the much higher inhibitory activity of aeruginosin 102-A than that of 298-A might be due to the effects of the sulfate moiety in the Hpla portion.
Conclusion
We developed a versatile synthetic process for aeruginosin 298-A as well as several attractive analogs, in which all stereocenters were controlled by catalytic asymmetric phase-transfer reaction and epoxidation. Drastic counter anion effects in PTC were observed for the first time, making it possible to threedimensionally fine-tune the catalyst 2 (ketal, Ar, and X). Furthermore, inhibitory activities against the serine protease trypsin were examined. The biologic activity studies of the newly synthesized aeruginosin analogs presented here suggest that conformation of the Argol portion, especially the guanidine side chain, is extremely important. Access to additional derivatives and closer investigation are now possible through the use of molecular design and chemical synthesis. Further studies on the structure-activity relation of aeruginosins and more attractive small-molecule analogs based on the current results along with previous biologic activity studies (7) and x-ray crystallographic structures of the serine protease-aeruginosin complex (41, 42) are currently under investigation in our group.
